Head and neck for Viralytics
Tuesday, 09 December, 2008
Sydney biotech Viralytics has been authorised to start a trial of its Cavatak oncolytic virus technology in head and neck cancers.
The company is running Phase I trials of the technology in late stage melanoma, prostate and breast cancers.
The new trial will involve nine patients with recurrent, inoperable tumours of the head and neck.
Cavatak is a coxsackievirus-based formulation which attaches itself to receptors on the cell surface that are highly expressed in some solid tumours.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
